Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for KORU Medical Systems, Inc. (NASDAQ: KRMD), a medical technology company focused on large-volume subcutaneous infusion solutions. These regulatory documents offer detailed information on the company’s operations, financial condition, risk factors, and material agreements related to its Freedom Syringe Infusion System and associated businesses.
Through its periodic reports, such as Form 10-K annual reports and Form 10-Q quarterly reports, KORU Medical discloses audited and interim financial statements, segment information for its core business and Pharma Services and Clinical Trials activities, and discussions of factors affecting demand for its subcutaneous infusion devices and services. These filings also describe the structure of the Freedom System, its regulatory status, and the company’s role in supporting large-volume subcutaneous drug delivery.
Form 8-K current reports document material events, including the public release of financial results, updated guidance, and key contracts. Recent 8-K filings have referenced press releases on preliminary and quarterly financial results and an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc., which covers the manufacture and supply of subassemblies, needle sets, and tubing products for KORU Medical.
Investors can also review proxy statements for information on executive compensation, equity awards, and corporate governance, as well as Form 4 insider transaction reports that show purchases, sales, or grants of KORU Medical common stock by directors and officers under the KRMD ticker.
On Stock Titan, KORU Medical’s SEC filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered tools can summarize lengthy filings such as 10-Ks and 10-Qs, highlight key sections on revenue drivers, manufacturing and supply arrangements, and non-GAAP metrics like adjusted EBITDA, and help users quickly locate discussions of regulatory submissions, pharma collaborations, and other factors relevant to KRMD’s subcutaneous infusion business.
KORU Medical Systems insider award summary: Adam R. Kalbermatten, the company’s Chief Commercial Officer, received a 300,000-share restricted stock award as an employment inducement and an option to buy 600,000 shares. The restricted shares vest 25% annually beginning July 28, 2026, subject to acceleration under his employment agreement. The option carries a $3.44 exercise price, a listed expiration of August 1, 2035, and a vesting schedule of one-fourth on August 1, 2026 and on each anniversary thereafter for three years.
What this means: The grants align compensation with future service and performance but create potential dilution of up to 900,000 shares if fully issued and exercised. Both holdings are reported as directly owned by the reporting person.
KORU Medical Systems, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Adam R. Kalbermatten. The Form 3 shows that, as of the event date of 07/28/2025, he beneficially owned 0 shares of KORU Medical common stock in direct ownership. This filing establishes his baseline reported ownership as a newly reported officer of the company.